{"id":982394,"date":"2026-07-16T18:38:08","date_gmt":"2026-07-16T22:38:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/"},"modified":"2026-07-16T18:38:08","modified_gmt":"2026-07-16T22:38:08","slug":"finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/","title":{"rendered":"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position:inside }\n.bwlistdisc { list-style-type: disc }\n.bwalignl { text-align: left }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio<\/b><\/p>\n<p class=\"bwalignc\"><i>Surveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settings<\/i><\/p>\n<p>AUSTIN, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54572158&amp;newsitemid=20260716661899&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=cb599037709525a7bf5276365f957cfb\">Natera, Inc.<\/a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.<\/p>\n<p>The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Kidney<\/b>: 6 tests in year 1; 4 per year in years 2-3. \u201cFor-cause\u201d coverage remains unchanged.<\/li>\n<li><b>Heart:<\/b> 12 tests in year 1; 4 per year in years 2-3. \u201cFor-cause\u201d coverage remains unchanged.<\/li>\n<li><b>Lung:<\/b> 12 tests in year 1; 4 per year in years 2-3 for both bilateral and single lung transplantation.<\/li>\n<\/ul>\n<p>The final LCD improves upon the July 2025 draft, which had suggested only 2 tests per year in years 2-3 across all indications; and only 4 tests in year 1 for kidney. Following the release of that draft in July 2025, major medical societies submitted comments to MolDx in support of coverage with expanded test frequency. These included letters from the American Society of Transplant Surgeons (ASTS), the American Society of Transplantation (AST), and the International Society of Heart &amp; Lung Transplantation (ISHLT).<\/p>\n<p>\u201cThe finalized LCD expands access to Prospera across critical post-transplant management settings,\u201d said Matt Mega, senior vice president of market access at Natera. \u201cThis new policy provides strong support for molecular testing in surveillance, thereby enabling clinicians to respond to rejection and help prevent irreversible damage to donor organs.\u201d<\/p>\n<p><b>About Natera<\/b><\/p>\n<p>Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54572158&amp;newsitemid=20260716661899&amp;lan=en-US&amp;anchor=www.natera.com&amp;index=2&amp;md5=9b88075a56d508365ce60709498c892b\">www.natera.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera\u2019s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in &#8220;Risk Factors&#8221; in Natera\u2019s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.natera.com%2Fnews%2Fdefault.aspx&amp;esheet=54572158&amp;newsitemid=20260716661899&amp;lan=en-US&amp;anchor=www.natera.com%2Finvestors&amp;index=3&amp;md5=5a7c6c936dc2d124a1d1cae341ffe989\">www.natera.com\/investors<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54572158&amp;newsitemid=20260716661899&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=c3b67ced4868396238711695d570ae54\">www.sec.gov<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260716661899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260716661899\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260716661899\/en\/<\/a><\/span><\/p>\n<p class=\"bwalignl\">Investor Relations: Mike Brophy, CFO, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:investor@natera.com\">investor@natera.com<\/a><br \/>Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:pr@natera.com\">pr@natera.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Texas United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Oncology Health Genetics Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260716661899\/en\/1736351\/3\/Natera_floret_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio Surveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settings AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060. The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes: Kidney: 6 tests in year 1; 4 per year in years 2-3. \u201cFor-cause\u201d coverage remains unchanged. Heart: 12 tests in year 1; 4 per year in years 2-3. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-982394","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio Surveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settings AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060. The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes: Kidney: 6 tests in year 1; 4 per year in years 2-3. \u201cFor-cause\u201d coverage remains unchanged. Heart: 12 tests in year 1; 4 per year in years 2-3. &hellip; Continue reading &quot;Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T22:38:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260716661899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio\",\"datePublished\":\"2026-07-16T22:38:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/\"},\"wordCount\":628,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260716661899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/\",\"name\":\"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260716661899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-07-16T22:38:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260716661899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260716661899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio - Market Newsdesk","og_description":"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio Surveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settings AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060. The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes: Kidney: 6 tests in year 1; 4 per year in years 2-3. \u201cFor-cause\u201d coverage remains unchanged. Heart: 12 tests in year 1; 4 per year in years 2-3. &hellip; Continue reading \"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-16T22:38:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260716661899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio","datePublished":"2026-07-16T22:38:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/"},"wordCount":628,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260716661899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/","name":"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260716661899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-07-16T22:38:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260716661899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260716661899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finalized-moldx-lcd-includes-expanded-coverage-for-nateras-prospera-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Finalized MolDx LCD Includes Expanded Coverage for Natera\u2019s Prospera\u2122 Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=982394"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982394\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=982394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=982394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=982394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}